The three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, including any allegations related to the subject intellectual property
The companies have also extended their long-standing commercial relationship by agreeing to collaborate on the sharing of specimen samples. (Credit: Scott Graham on Unsplash)
Guardant Health, a leading precision oncology company, today announced an agreement with Illumina, a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership.
The three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, including any allegations related to the subject intellectual property. The companies have also extended their long-standing commercial relationship by agreeing to collaborate on the sharing of specimen samples to advance cancer research, and by entering into a new long-term purchase and supply commitment.
“Both companies are deeply committed to our collaboration to help patients and conquer cancer,” said Chris Freeman, chief commercial officer of Guardant. “This agreement supports getting our transformative technologies to even more patients globally, while strengthening our long-standing and valued partnership with Illumina.”
Source: Company Press Release